
-
Xoma Corporation NasdaqGM:XOMA XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Location: 2200 Powell Street, Emeryville, CA, 94608, United States | Website: https://www.xoma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
344.8M
Cash
92.65M
Avg Qtr Burn
-1.651M
Short % of Float
2.24%
Insider Ownership
0.80%
Institutional Own.
65.91%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vudalimab (PD-1 x CTLA-4) Details Non-small cell lung carcinoma | Phase 2 Data readout | |
Vudalimab (PD-1 x CTLA-4) Details Castration-resistant prostate cancer | Phase 2 Data readout | |
XmAb564 (IL2-Fc) Details Atopic dermatitis, Psoriasis | Phase 1b Data readout | |
XmAb662 (IL12-Fc) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
XmAb541 Details Cancer, Ovarian cancer | Phase 1 Data readout | |
Plamotamab (CD20 x CD3) +tafasitamab plus lenalidomide Details Cancer, Diffuse large B cell lymphoma | Failed Discontinued |